	US 12,097,227 B2
	*Nanovesicles derived from bacteria of Lactococcus* genus and use thereof**
Yoon-Keun Kim, Paju-Si (KR); and Hae-Sim Park, Seoul (KR)
Assigned to MD HEALTHCARE INC., Seoul (KR)
Appl. No. 16/968,058
Filed by MD HEALTHCARE INC., Seoul (KR)
PCT Filed Feb. 1, 2019, PCT No. PCT/KR2019/001439 § 371(c)(1), (2) Date Aug. 6, 2020, PCT Pub. No. WO2019/156449, PCT Pub. Date Aug. 15, 2019.
Claims priority of application No. 10-2018-0015382 (KR), filed on Feb. 8, 2018; and application No. 10-2019-0012758 (KR), filed on Jan. 31, 2019.
Prior Publication US 2021/0052675 A1, Feb. 25, 2021
Int. Cl. A61K 35/744 (2015.01); A61K 9/00 (2006.01); C12Q 1/686 (2018.01)

CPC A61K 35/744 (2013.01) [A61K 9/0073 (2013.01); C12Q 1/686 (2013.01); G01N 2800/2835 (2013.01); G01N 2800/2871 (2013.01); G01N 2800/304 (2013.01); G01N 2800/324 (2013.01); G01N 2800/326 (2013.01); G01N 2800/347 (2013.01)]

4 Claims

1. A method of alleviating or treating inflammatory disease, the method comprising administering to a subject in need thereof a composition comprising an effective amount of vesicles derived from Lactococcus lactis,

wherein the inflammatory disease is mediated by interleukin-6 (IL-6) or tumor necrosis factor-α (TNF-α).